search icon
edsa-img

Edesa Biotech Inc, Common Stock

EDSA

NAQ

$1.5899

-$0.14

(-8.09%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
20.02K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.55 L
$5.99 H
$1.5899

About Edesa Biotech Inc, Common Stock

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEDSASectorS&P500
1-Week Return-15.9%0.31%-1.26%
1-Month Return-16.32%0.6%-4.16%
3-Month Return-63.03%-9.44%-0.46%
6-Month Return-62.5%-5.15%3.58%
1-Year Return-65.96%0.33%22.47%
3-Year Return-95.68%4.53%25.13%
5-Year Return-93.62%35.98%77.7%
10-Year Return-99.95%100.72%190.12%

Financials

Sep '20Sep '21Sep '22Sep '23Sep '245YR TREND
Total Revenue328.80K500.00---[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":0.15,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Cost of Revenue17.60K118.79K118.19K183.47K-[{"date":"2020-09-30","value":9.59,"profit":true},{"date":"2021-09-30","value":64.74,"profit":true},{"date":"2022-09-30","value":64.42,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Profit311.20K(118.79K)(118.19K)(183.47K)-[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":-38.17,"profit":false},{"date":"2022-09-30","value":-37.98,"profit":false},{"date":"2023-09-30","value":-58.96,"profit":false},{"date":"2024-09-30","value":"-","profit":true}]
Gross Margin94.65%(23757.60%)(Infinity%)(Infinity%)-[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":-25101.29,"profit":false},{"date":"2022-09-30","value":null,"profit":false},{"date":"2023-09-30","value":null,"profit":false},{"date":"2024-09-30","value":"-","profit":true}]
Operating Expenses6.71M13.34M17.59M9.22M7.01M[{"date":"2020-09-30","value":38.16,"profit":true},{"date":"2021-09-30","value":75.84,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":52.43,"profit":true},{"date":"2024-09-30","value":39.88,"profit":true}]
Operating Income(6.40M)(23.68M)(18.37M)(9.22M)(7.01M)[{"date":"2020-09-30","value":-640084200,"profit":false},{"date":"2021-09-30","value":-2368133200,"profit":false},{"date":"2022-09-30","value":-1837079000,"profit":false},{"date":"2023-09-30","value":-922275800,"profit":false},{"date":"2024-09-30","value":-701474400,"profit":false}]
Total Non-Operating Income/Expense75.19K10.35M886.19K1.14M999.00K[{"date":"2020-09-30","value":0.73,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":8.56,"profit":true},{"date":"2023-09-30","value":11,"profit":true},{"date":"2024-09-30","value":9.65,"profit":true}]
Pre-Tax Income(6.36M)(13.34M)(17.55M)(8.37M)(6.17M)[{"date":"2020-09-30","value":-636343000,"profit":false},{"date":"2021-09-30","value":-1334235000,"profit":false},{"date":"2022-09-30","value":-1754812400,"profit":false},{"date":"2023-09-30","value":-837361500,"profit":false},{"date":"2024-09-30","value":-616924500,"profit":false}]
Income Taxes800.00800.00800.00800.00800.00[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Income After Taxes(6.36M)(13.34M)(17.55M)(8.37M)(6.17M)[{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}]
Income From Continuous Operations(6.36M)(13.34M)(17.55M)(8.37M)(6.17M)[{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(6.36M)(13.34M)(17.55M)(8.37M)(6.17M)[{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}]
EPS (Diluted)(0.74)(1.70)(1.05)(0.95)(1.93)[{"date":"2020-09-30","value":-74,"profit":false},{"date":"2021-09-30","value":-170,"profit":false},{"date":"2022-09-30","value":-105,"profit":false},{"date":"2023-09-30","value":-95,"profit":false},{"date":"2024-09-30","value":-193,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EDSA
Cash Ratio 0.57
Current Ratio 0.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EDSA
ROA (LTM) -71.52%
ROE (LTM) -129.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EDSA
Debt Ratio Lower is generally better. Negative is bad. 0.48
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.52

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EDSA
Trailing PE NM
Forward PE 0.17
P/S (TTM) 120477.93
P/B 3.03
Price/FCF NM
EV/R 128525.38
EV/Ebitda NM

FAQs

What is Edesa Biotech Inc share price today?

Edesa Biotech Inc (EDSA) share price today is $1.5899

Can Indians buy Edesa Biotech Inc shares?

Yes, Indians can buy shares of Edesa Biotech Inc (EDSA) on Vested. To buy Edesa Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EDSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Edesa Biotech Inc be purchased?

Yes, you can purchase fractional shares of Edesa Biotech Inc (EDSA) via the Vested app. You can start investing in Edesa Biotech Inc (EDSA) with a minimum investment of $1.

How to invest in Edesa Biotech Inc shares from India?

You can invest in shares of Edesa Biotech Inc (EDSA) via Vested in three simple steps:

  • Click on Sign Up or Invest in EDSA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Edesa Biotech Inc shares
What is Edesa Biotech Inc 52-week high and low stock price?

The 52-week high price of Edesa Biotech Inc (EDSA) is $5.99. The 52-week low price of Edesa Biotech Inc (EDSA) is $1.55.

What is Edesa Biotech Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Edesa Biotech Inc (EDSA) is

What is Edesa Biotech Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Edesa Biotech Inc (EDSA) is 3.03

What is Edesa Biotech Inc dividend yield?

The dividend yield of Edesa Biotech Inc (EDSA) is 0.00%

What is the Market Cap of Edesa Biotech Inc?

The market capitalization of Edesa Biotech Inc (EDSA) is $5.51M

What is Edesa Biotech Inc’s stock symbol?

The stock symbol (or ticker) of Edesa Biotech Inc is EDSA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top